Sage Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	3.83	3.46	3.96	0.88
Other Revenue	0.58	0.16	0.05	0.04
Revenue	4.42	3.62	4.02	0.91
Revenue Growth (YoY)	22.04%	-9.93%	339.35%	-
Selling, General & Admin	0.31	0.21	0.14	0.08
Depreciation & Amortization	0.08	0.07	0.07	0.06
Amortization of Goodwill & Intangibles	1.55	0.41	0.39	0.11
Other Operating Expenses	-5.28	-1.65	2.28	1.89
Total Operating Expenses	-3.35	-0.95	2.88	2.14
Operating Income	7.77	4.57	1.14	-1.22
Interest Expense	-1.68	-0.27	-0.77	-0.35
Net Interest Expense	-1.68	-0.27	-0.77	-0.35
Income (Loss) on Equity Investments	0.02	-	0.05	5.05
Currency Exchange Gain (Loss)	0.22	-0.07	0	-0
Other Non-Operating Income (Expenses)	0.05	0.1	0	0.01
EBT Excluding Unusual Items	6.38	4.33	0.43	3.49
Gain (Loss) on Sale of Investments	-0.41	-	-0.05	-
Pretax Income	5.97	4.33	0.38	3.49
Income Tax Expense	2.65	1.3	0.1	0.02
Earnings From Continuing Ops.	3.32	3.03	0.27	3.47
Minority Interest in Earnings	-0.42	-0.79	-0.01	0.01
Net Income	2.9	2.24	0.26	3.48
Net Income to Common	2.9	2.24	0.26	3.48
Net Income Growth	29.35%	753.61%	-92.46%	-
Shares Outstanding (Basic)	-	8	-	-
Shares Outstanding (Diluted)	-	8	-	-
EPS (Basic)	-	0.27	-	-
EPS (Diluted)	-	0.27	-	-
Free Cash Flow	-12.31	-2.09	-0.72	-1.04
Free Cash Flow Per Share	-	-0.26	-	-
Profit Margin	65.66%	61.95%	6.54%	381.07%
Free Cash Flow Margin	-278.82%	-57.77%	-18.04%	-113.60%
EBITDA	9.14	5.05	1.6	-0.96
EBITDA Margin	207.01%	139.67%	39.73%	-105.18%
D&A For EBITDA	1.37	0.49	0.46	0.26
EBIT	7.77	4.57	1.14	-1.22
EBIT Margin	175.88%	126.19%	28.33%	-133.55%
Effective Tax Rate	44.40%	29.97%	27.63%	0.47%
Revenue as Reported	19.82	10.91	4.51	0.92

Source: S&P Global Market Intelligence. Utility template. Financial Sources.